thyroid eye disease

Acelyrin adds proof-of-concept TED data to recent readout pile, cementing challenge to Amgen
Fierce Biotech
Wed, 03/20/24 - 11:50 am
Acellyrin
thyroid eye disease
clinical trials
lonigutamab
Amgen
Innovent's Tepezza rival one step closer to Chinese approval after phase 3 eye disease win
Fierce Biotech
Tue, 02/20/24 - 05:51 pm
Innovent Biologics
thyroid eye disease
Tepezza
China
Amgen
IBI311
Key Horizon drug Tepezza has hearing loss warning added to labeling
Seeking Alpha
Thu, 07/20/23 - 09:46 pm
Horizon Therapeutics
Tepezza
hearing loss
thyroid eye disease
A chronic disappointment for Viridian
EP Vantage
Wed, 07/12/23 - 09:27 am
Viridian Therapeutics
VRDN-001
thyroid eye disease
Viridian Poised to Challenge Horizon in Thyroid Eye Disease
BioSpace
Tue, 07/11/23 - 10:01 am
Viridian Therapeutics
VRDN-001
thyroid eye disease
Horizon Therapeutics
Viridian aims to prove itself in thyroid eye
EP Vantage
Thu, 04/20/23 - 10:41 am
Viridian Therapeutics
thyroid eye disease
Horizon Therapeutics
Tepezza
VRDN-001
Horizon's (HZNP) Tepezza Meets Goals in TED Expanded Use Study
Zacks.com
Tue, 04/11/23 - 11:28 am
Horizon Therapeutics
Tepezza
clinical trials
thyroid eye disease
Viridian takes on Horizon
EP Vantage
Tue, 08/16/22 - 10:49 am
Horizon Therapeutics
Virdian
thyroid eye disease
VRDN-001
Tepezza
Horizon teams up with Olympic champion to raise awareness around Graves' disease and thyroid eye disease
Fierce Pharma
Mon, 07/12/21 - 10:36 am
Horizon Therapeutics
Graves' disease
thyroid eye disease
Horizon lays out $65M for in-house manufacturing plant as eye med Tepezza resets course to blockbusterland
Fierce Pharma
Wed, 06/23/21 - 11:01 am
Horizon Therapeutics
drug manufactruing
Tepezza
thyroid eye disease
Immunovant flashes the data that made Roivant want to reacquire it at a potentially hefty premium
Endpoints
Tue, 06/1/21 - 10:53 pm
Immunovant
Roivant
myasthenia gravis
thyroid eye disease
Immunovant stock loses half its value after pausing dosing in trial of thyroid eye disease treatment
Marketwatch
Tue, 02/2/21 - 10:42 am
Immunovant
thyroid eye disease
clinical trials
IMVT-1401
Horizon switched up strategy for Tepezza launch, moving quickly to DTC to reach eye disease patients
Fierce Pharma
Tue, 01/19/21 - 10:44 am
Horizon Pharma
thyroid eye disease
Tepezza
drug launches
DTC
Newly-public Immunovant announces first proof-of-concept success
Endpoints
Mon, 03/30/20 - 10:38 am
Immunovant
thyroid eye disease
IMVT-1401
clinical trials
FDA Approves First-Ever Treatment for Thyroid Eye Disease
Motley Fool
Tue, 01/21/20 - 11:50 pm
Horizon Therapeutics
Tepezza
thyroid eye disease
FDA
FDA expert panel unanimously recommends approval for Horizon Therapeutics eye drug
Endpoints
Fri, 12/13/19 - 09:32 pm
FDA
advisory panels
Horizon Therapeutics
thyroid eye disease
teprotumumab
FDA in-house review spotlights an issue with one of Horizon's endpoints but notes efficacy for lead drug
Endpoints
Thu, 12/12/19 - 11:01 am
FDA
Horizon Pharma
clinical trials
teprotumumab
thyroid eye disease
Horizon secures FDA priority review for teprotumumab for treatment of active thyroid eye disease
Pharmaceutical Business Review
Tue, 09/10/19 - 09:41 am
Horizon Therapeutics
FDA
teprotumumab
thyroid eye disease
priority review
Horizon Pharma’s Thyroid Eye Disease Treatment Could Become a Blockbuster, Analyst Predicts
BioSpace
Mon, 04/29/19 - 09:37 pm
Horizon Pharma
thyroid eye disease
teprotumumab
After thyroid eye drug scores in PhIII test, Horizon Pharma readies marketing application
Endpoints
Fri, 03/1/19 - 09:29 am
thyroid eye disease
Horizon Pharma
teprotumumab

Pages